长期3,5-二碘甲状腺原氨酸治疗对正常饮食和高脂饮食小鼠肝脏蛋白质组和转录组的比较分析
该研究对高脂饮食诱导NAFLD的雄性C57BL/6小鼠及标准饮食对照,给予2.5 μg/g体重3,5-T2或生理盐水4周,整合肝脏蛋白质组与转录组数据。结果显示3,5-T2降低肝脂并影响氧化应激和载脂蛋白谱,同时诱导胆固醇、胆汁酸及雄性性激素合成相关基因,提示肝脏「男性化」潜在风险。
要点
- 3,5-T2降低高脂饮食小鼠肝脏脂肪含量,并减少氧化应激、改变载脂蛋白谱。
- 3,5-T2诱导胆固醇和胆汁酸合成基因,可能促进胆汁酸排泄。
- 高脂饮食下3,5-T2增强肝脏雄性性激素暴露,潜在后果尚不明确。
核心结论
- 3,5-T2除诱导脂肪酸氧化外,还刺激胆固醇和胆汁酸合成及胆汁排泄,可能是其降肝脂的重要机制。
- 3,5-T2治疗的HFD动物肝脏雄性性激素暴露增强,可能加剧肝脏「男性化」,生理后果尚不明确。
研究设计与样本
- 雄性C57BL/6小鼠喂饲高脂饮食诱导NAFLD或标准饮食作为对照,给予2.5 μg/g体重3,5-T2或生理盐水4周。
- 对肝脏进行质谱蛋白质组分析,并与同一动物既往发表的微阵列转录组数据整合。
- 用气相色谱-串联质谱测定血清和不同组织中的多种性激素浓度。
主要发现
- 3,5-T2治疗下差异丰度的转录本与蛋白质一致性有限,部分可由方法学原因解释,也可能反映非经典转录后事件。
- 与标准饮食相比,高脂饮食下3,5-T2影响更多且部分不同的蛋白质,显示肝脏脂质负荷调节其反应。
- 组学数据提示3,5-T2降低氧化应激并改变载脂蛋白谱,均源于肝脂含量降低。
- 观察到经典甲状腺激素靶基因及胆固醇、胆汁酸和雄性性激素生物合成相关基因诱导,后者得到肝脏性激素测定支持。
临床怎么用
- 3,5-T2改善肝脏脂肪变性的同时可能影响胆固醇/胆汁酸代谢及肝脏性激素环境,临床转化需评估这些额外效应。
局限性
- 转录本与蛋白质一致性有限,部分机制推断受方法学限制。
- 肝脏「男性化」的生理后果尚不明确,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The thyroid hormone (TH) metabolite 3,5-diiodothyronine (3,5-T2) is considered as a potential drug for treatment of nonalcoholic fatty liver disease (NAFLD) based on its prominent antisteatotic effects in murine models of obesity without the detrimental thyromimetic side effects known for classical TH. To expand our understanding of its mode of action, we comprehensively characterized the effects of 3,5-T2 on hepatic gene expression in a diet-induced murine model of obesity by a combined liver proteome and transcriptome analysis. Materials and Methods: Male C57BL/6 mice fed high-fat diet (HFD) to induce NAFLD or standard diet (SD) as control were treated with 2.5 μg/g body weight 3,5-T2 or saline for 4 weeks. We performed mass spectrometry analyses and integrated those proteome data with earlier published microarray-based transcriptome data from the same animals. In addition, concentrations of several sex steroids in serum and different tissues were determined by gas chromatography-tandem mass spectrometry. Results: We observed limited concordance between transcripts and proteins exhibiting differential abundance under 3,5-T2 treatment, which was only partially explainable by methodological reasons and might, therefore, reflect noncanonical post-transcriptional events. The treatment affected the levels of more and partially different proteins under HFD as compared with SD, demonstrating response modulation by the hepatic lipid load. The hepatic physiological signatures of 3,5-T2 treatment inferable from the omics data comprised the reduction of oxidative stress and alteration of apolipoprotein profiles, both due to decreased liver fat content. In addition, induction of several classical TH target genes and genes involved in the biosynthesis of cholesterol, bile acids (BAs), and male sex steroids was observed. The latter finding was supported by hepatic sex steroid measurements. Conclusion: While confirming the beneficial hepatic liver fat reduction by 3,5-T2 treatment, our data suggest that besides the well-known induction of fatty acid oxidation the stimulation of cholesterol- and BA synthesis with subsequent excretion of the latter through bile might represent a further important mechanism in this context. The obvious intensified male sex steroid exposition of the liver in 3,5-T2-treated HFD animals can be predicted to cause enhanced hepatic "masculinization," with not yet clear but potentially detrimental physiological consequences.
引用
- Lietzow J, Golchert J, Pietzner M, et al. Comparative Analysis of the Effects of Long-Term 3,5-diiodothyronine Treatment on the Murine Hepatic Proteome and Transcriptome Under Conditions of Normal Diet and High-Fat Diet. Thyroid. 2021. PMID: 33637021. doi:10.1089/thy.2020.0160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。